Abstract:Objective To further analyze the prognostic factors in stage Ⅳ non-small cell lung cancer (NSCLC) treated by chemotherapy with concurrent three-dimensional radiotherapy.Methods We enrolled 201 patients with stage Ⅳ NSCLC in this study from January 2003 to July 2010 and analyzed overall survival (OS) in 159 patients (three-dimensional radiotherapy ＞ 36 Gy) and progression-free survival (PFS) in 120 patients.Platinum-based doublets chemotherapy was performed,and the median number of cycles was 4 ; the median dose to the planning target volume was 63 Gy.Survival rates were calculated by the Kaplan-Meier method and compared by the log-rank test.The time of multivariate prognostic analysis with the Cox model was increased from 3 years to 5 years.Results The 1-,2-,3-,and 5-year OS rates were 40.1％,17.3％,10.2％,and 5.1％,respectively,and the median survival time was 10 months.The short-term complete response,partial response,stable disease,and progressive disease rates were 7.5％,66.0％,19.5％,and 6.9％,respectively,and the median survival times were 19,13,8,and 6 months,respectively (P =0.000).The 1-,2-,3-,and 5-year PFS rates and median survival times of patients undergoing 4 to 5 cycles of chemotherapy with radiotherapy doses of ≥63 Gy and ＜ 63 Gy were 77.4％ vs.32.6％,36.2％ vs.21.7％,27.2％ vs.0％,15.9％ vs.0％,and 20 vs.9 months,respectively (P =0.002).According to multivariate analysis,4 to 5 cycles of chemotherapy,stable or increased Karnofsky Performance Scale score after treatment,and gross tumor volume ＜ 175 cm3 were independent prognostic factors for a better OS (P =0.035,0.000,and 0.008,respectively).Radiation dose to the primary tumor ≥ 63 Gy resulted in a better PFS (P =0.051),which was of borderline significance.Conclusions Chemotherapy (4-5 cycles) with concurrent three-dimensional radiotherapy (≥ 63 Gy) may significantly prolong PFS and OS in patients with stage Ⅳ NSCLC.

Prognostic Reanalysis of Stage Ⅳ Non-Small Cell Lung Cancer Treated by Chemotherapy with Concurrent Three-Dimensional Radiotherapy